Celularity (CELU) Treasury Shares (2019 - 2025)

Celularity (CELU) posted quarterly Treasury Shares of $256000.0 for Q4 2020, little changed quarter-over-quarter from $256000.0 in Q3 2020.

Celularity (CELU) Treasury Shares (2019 - 2025) Analysis & Trends

Celularity (CELU) has reported Treasury Shares for 1 consecutive years, with $256000.0 the latest figure, recorded in Q4 2020.

In Q4 2025, Treasury Shares fell 95.65% year-over-year to $28665.0; the TTM figure through Dec 2025 stood at $28665.0 (down 95.65% YoY), while the FY2025 annual figure was $28665.0, down 95.65% from the prior year.
Treasury Shares slipped to $28665.0 in Q4 2025 per CELU's latest filing, from $488161.0 in the prior quarter.
Across five years, Treasury Shares topped out at $41.2 million in Q1 2021 and bottomed at $28665.0 in Q4 2025.
Historically, Treasury Shares has averaged $4.4 million across 5 years, with a median of $581832.0 in 2025.
Annual changes were most pronounced in 2022 — Treasury Shares plunged 98.74% — and 2023, when it jumped 1023.42%.
Celularity's Treasury Shares stood at $474700.0 in 2021, then tumbled by 52.18% to $227013.0 in 2022, then jumped by 262.68% to $823332.0 in 2023, then slipped by 19.91% to $659439.0 in 2024, then plunged by 95.65% to $28665.0 in 2025.
Business Quant data shows CELU's Treasury Shares at $28665.0 in Q4 2025, $488161.0 in Q3 2025, and $558530.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.94 Bn	132.09 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.59 Bn	78.60 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	65.67 Bn	60.49 Bn	1.37 Bn	-
4	Moderna	57.81 Bn	52.67 Bn	52.00 Mn	-
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	-
7	BioNTech SE	28.41 Bn	10.02 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	-
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	2.72 Mn
10	Celularity	21.75 Mn	15.58 Mn	-3.27 Mn	-

Download Data